

TECHNICAL SPECIFICATIONS


Drug / Excipient	
Drug	Sirolimus
Drug Dose	1.12 µg/mm²
Drug Carrier	Phospholipid based excipient
Stent	
Stent Material	L605 Cobalt Chromium Alloy
Strut Thickness	73 µm
Strut Width	80 µm (hinge)-120 µm (strut)

Delivery System	
Delivery System	RX stent delivery system
Nominal Pressure	8 bar
Rated Burst Pressure	14 bar*
Guidewire compatibility (max.)	0.014"
Guiding Catheter Compatibility	5F
Crossing Profile**	0.038"
Tip Entry Profile	0.016"

* Do not exceed RBP
** Reference Diameter of 3.00 mm

ORDERING INFORMATION

Stent Dia (mm)	Stent Length (mm)								
	08	12	16	20	24	28	32	36	40
2.25	EFO22508	EFO22512	EFO22516	EFO22520	EFO22524	EFO22528	EFO22532	EFO22536	EFO22540
2.50	EFO25008	EFO25012	EFO25016	EFO25020	EFO25024	EFO25028	EFO25032	EFO25036	EFO25040
2.75	EFO27508	EFO27512	EFO27516	EFO27520	EFO27524	EFO27528	EFO27532	EFO27536	EFO27540
3.00	EFO30008	EFO30012	EFO30016	EFO30020	EFO30024	EFO30028	EFO30032	EFO30036	EFO30040
3.50	EFO35008	EFO35012	EFO35016	EFO35020	EFO35024	EFO35028	EFO35032	EFO35036	EFO35040
4.00	EFO40008	EFO40012	EFO40016	EFO40020	EFO40024	EFO40028	EFO40032	EFO40036	EFO40040



*The above diagram is just an illustration of the product.
Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.



Concept Medical

f t i n /conceptmedicals

✉ info@conceptmedical.com

🌐 www.conceptmedical.com

Scan for more details



CB.BA.FO.BRO.ver.1.0.21-02

Concept Medical

FOCUS NP
SIROLIMUS BASED NANO CARRIER ELUTING STENT SYSTEM

NON-POLYMER

FOCUS NP

FOCUS NP DEALS WITH HARD FACTS

HEALING DELAYED



ABLUMINAL COATING

Drug is coated on the abluminal side only
Leading to unidirectional drug release
and less systemic exposure of drug
which leads to faster healing

ACUTE / SUB ACUTE / LATE THROMBOSIS



FUSION COATING

(Drug is coated on stent as well as exposed
parts of balloon and coated 0.5mm additional
on the proximal and distal end of the stent)
Helps to address the entire diseased area
of lesion and address the focal restenosis
and edge restenosis

POLYMER FREE NANO CARRIER DRUG DELIVERY MATRIX


Designed for acute as well as sustained drug
transfer in arterial wall - leading to less chronic
inflammation and improved vascular healing




POLYMER FREE COATING

Proposed the shorter DAPT which helps
to reduce bleeding risk in patients with
high bleeding risk.


MECHANISM OF ACTION




Step 1: Burst drug release from stent and
parts of balloon at the time of stent deployment
45 Second inflation holding time recommended



Step 2: Drug release from stent and parts
of balloon upon expansion




Step 3: Longer duration Drug release from stent



Step 4: Converts to BMS @ 40 days

NANOACTIVE COATING TECHNOLOGY



ADVANTAGE OF NANOACTIVE TECHNOLOGY

- Better in-tissue bioavailability of drug
- Effective drug transfer to the deepest layer of the vessel
- Reduces drug dose
- Protect drug by encapsulation – reduced in-transit drug loss